United States  

“News neutrality by unbiased coverage”
One News Page
Regeneron News 
0
shares
ShareTweetSavePostSend
 

Meet Regeneron's corporate problem solver

Christine Childrose’s human resources career has taken her from General Electric and Albany Molecular Research Inc. to Regeneron Pharmaceuticals, one of the region’s fastest-growing companies.
Credit: bizjournals - Published

Plug Power, Regeneron held on to more cash this year

Political uncertainty and trade tensions with China have prompted many businesses to take a conservative cash position in recent months, bucking predictions that last year's tax-reform law would spur..
Credit: bizjournals - Published

Videos for regeneron

Nasdaq 100 Movers: COST, REGN [Video]Nasdaq 100 Movers: COST, REGN  01:07

In early trading on Friday, shares of Regeneron Pharmaceuticals topped the list of the day's best performing components of the Nasdaq 100 index, trading up 1.6%. Year to date, Regeneron Pharmaceuticals..

Credit: Market News Video - Published

S&P 500 Movers: DG, AZO [Video]S&P 500 Movers: DG, AZO  01:26

In early trading on Tuesday, shares of AutoZone, topped the list of the day's best performing components of the S&P 500 index, trading up 4.8%. Year to date, AutoZone, registers a 21.4% gain.

Credit: Market News Video - Published

Nasdaq 100 Movers: ATVI, KHC [Video]Nasdaq 100 Movers: ATVI, KHC  01:06

In early trading on Monday, shares of Kraft Heinz (KHC) topped the list of the day's best performing components of the Nasdaq 100 index, trading up 2.2%. Year to date, Kraft Heinz has lost about 33.3%..

Credit: Market News Video - Published

Nasdaq 100 Movers: ALGN, XLNX [Video]Nasdaq 100 Movers: ALGN, XLNX  01:06

In early trading on Thursday, shares of Xilinx (XLNX) topped the list of the day's best performing components of the Nasdaq 100 index, trading up 14.7%. Year to date, Xilinx registers a 17.5% gain.

Credit: Market News Video - Published

 

Bluebird Bio unveils new data evaluating its LentiGlobin gene therapy in patients with blood disorders

Shares of Bluebird Bio (NASDAQ:BLUE) slipped Monday in the wake of the unveiling of new data which evaluated the company’s LentiGlobin gene therapy in patients with both transfusion-dependent..
Credit: Proactive Investors - Published

Better Buy: Vertex Pharmaceuticals vs. Regeneron Pharmaceuticals

Two big biotechs. One clear winner.
Credit: Motley Fool - Published

Regeneron: Regenerating As Usual


Credit: SeekingAlpha - Published

British genetic database expects $320 million investment

U.K. Biobank, a huge collection of patients’ health and genetic information, is expected to attract as much as $320 million in investment as Britain tries to bolster its life-sciences sector with..
Credit: SFGate - Published

Regeneron Pharmaceuticals, Inc. (REGN) CEO Leonard Schleifer Presents at Piper Jaffray 30th Annual Healthcare Conference (Transcript)


Credit: SeekingAlpha - Published

Ziopharm: Elucidating The Regeneron Partnership For Glioblastoma


Credit: SeekingAlpha - Published

Biotech Bio Series #4: Regeneron Is Not Done


Credit: SeekingAlpha - Published

Regeneron: More Downside Ahead


Credit: SeekingAlpha - Published

Inovio Pharmaceuticals reports narrower net loss in 3Q as R&D expenses decrease

Inovio Pharmaceuticals Inc (NASDAQ:INO) topped earnings expectations in its third-quarter results as research and development expenses decreased. The biotech reported a net loss of $0.27 per share on..
Credit: Proactive Investors - Published

Asthma and Allergy Foundation of America & PlatformQ Health to Share Live-Online Patient Education Program on Eczema

Program designed to help millions of affected patients and caregivers better understand and manage this skin condition BOSTON (PRWEB) November 07, 2018 The Asthma and Allergy Foundation of..
Credit: PRWeb - Published

Regeneron Reports Q3: Updating Its Growth Prospects


Credit: SeekingAlpha - Published

Regeneron Pharmaceuticals (REGN) Q3 2018 Results - Earnings Call Transcript


Credit: SeekingAlpha - Published Also reported by •Motley Fool

Regeneron Pharmaceuticals tops 3Q earnings and revenue estimates; shares edge higher

Regeneron Pharmaceuticals Inc's (NASDAQ:REGN) third-quarter results topped both their earnings and revenue forecasts on stronger sales of their medical products, with shares getting a modest boost in..
Credit: Proactive Investors - Published

Regeneron files U.S. application for expanded use for Dupixent


Credit: SeekingAlpha - Published

Regeneron Q3 top line up 11%; earnings up 53%


Credit: SeekingAlpha - Published

Clearside Biomedical shares slide after failed Phase 3 trial, but a plan B is in the works

Clearside Biomedical Inc (NASDAQ:CLSD) shares tanked after its Phase 3 clinical trial didn’t go according to plan. Shares of the Georgia-based biopharma fell nearly 50% to $2.90 in Monday pre-market..
Credit: Proactive Investors - Published

Adverum Biotechnologies shares fall after after treatment for liver or lung disease fails

Adverum Biotechnologies Inc (NASDAQ:ADVM) shares tumbled on Friday after the company announced it will not continue development of a gene therapy program to treat A1AT for liver or lung disease. "While..
Credit: Proactive Investors - Published

Sanofi's Q3 Dupixent sales could boost Regeneron - Cantor


Credit: SeekingAlpha - Published

You Might Like


 Page 1  〉 
Environmentally friendly: One News Page is hosted on servers powered solely by renewable energy
© 2018 One News Page Ltd. All Rights Reserved.
About us  |  Contact us  |  Disclaimer  |  Press Room  |  Terms & Conditions  |  Content Accreditation
 RSS  |  News for my Website  |  Free news search widget  |  Contact us  |  DMCA / Content Removal  |  Privacy & Data Protection Policy
How are we doing? Send us your feedback  |   LIKE us on Facebook   FOLLOW us on Twitter  •  FOLLOW us on Pinterest